Verona Ebitda vs Selling And Marketing Expenses Analysis

VRNA Stock

USD 38.81 0.95 2.51%

Verona Pharma financial indicator trend analysis is much more than just breaking down Verona Pharma PLC prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Verona Pharma PLC is a good investment. Please check the relationship between Verona Pharma Ebitda and its Selling And Marketing Expenses accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Verona Pharma PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Ebitda vs Selling And Marketing Expenses

Ebitda vs Selling And Marketing Expenses Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Verona Pharma PLC Ebitda account and Selling And Marketing Expenses. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Verona Pharma's Ebitda and Selling And Marketing Expenses is 0.57. Overlapping area represents the amount of variation of Ebitda that can explain the historical movement of Selling And Marketing Expenses in the same time period over historical financial statements of Verona Pharma PLC, assuming nothing else is changed. The correlation between historical values of Verona Pharma's Ebitda and Selling And Marketing Expenses is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Ebitda of Verona Pharma PLC are associated (or correlated) with its Selling And Marketing Expenses. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Selling And Marketing Expenses has no effect on the direction of Ebitda i.e., Verona Pharma's Ebitda and Selling And Marketing Expenses go up and down completely randomly.

Correlation Coefficient

0.57

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Ebitda

Selling And Marketing Expenses

Most indicators from Verona Pharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Verona Pharma PLC current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Verona Pharma PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

At present, Verona Pharma's Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Tax Provision is expected to grow to about 582.8 K, whereas Sales General And Administrative To Revenue is forecasted to decline to 17.17.

	2021	2022	2023	2024 (projected)
Research Development	79.4M	49.3M	17.3M	19.8M
Depreciation And Amortization	629K	636K	679.6K	713.6K

Research Development Depreciation And Amortization

Verona Pharma fundamental ratios Correlations

	Total Assets	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Other Current Liab	Property Plant And Equipment Net	Good Will	Short Term Investments	Property Plant And Equipment Gross	Intangible Assets	Net Tangible Assets
Total Assets		0.54	1.0	-0.97	-0.97	0.51	0.98	0.86	0.92	0.33	1.0	0.79	-0.42	0.33	0.9	0.99	0.94	1.0	0.98	0.51	0.86	-0.76	0.26	0.9	0.88	1.0
Total Current Liabilities	0.54		0.54	-0.55	-0.55	0.81	0.47	0.51	0.61	0.3	0.51	0.78	-0.21	0.71	0.59	0.54	0.5	0.53	0.55	0.98	0.26	-0.76	0.28	0.23	0.72	0.53
Total Stockholder Equity	1.0	0.54		-0.97	-0.96	0.48	0.98	0.83	0.93	0.35	1.0	0.78	-0.43	0.35	0.91	0.99	0.91	1.0	0.98	0.51	0.83	-0.75	0.27	0.87	0.87	0.99
Net Debt	-0.97	-0.55	-0.97		0.96	-0.46	-0.99	-0.83	-0.97	-0.36	-0.97	-0.74	0.36	-0.44	-0.87	-0.97	-0.88	-0.97	-0.99	-0.53	-0.82	0.69	-0.07	-0.87	-0.83	-0.98
Retained Earnings	-0.97	-0.55	-0.96	0.96		-0.58	-0.97	-0.92	-0.94	-0.29	-0.96	-0.84	0.45	-0.41	-0.81	-0.99	-0.94	-0.96	-0.98	-0.51	-0.89	0.7	-0.11	-0.89	-0.86	-0.98
Accounts Payable	0.51	0.81	0.48	-0.46	-0.58		0.45	0.7	0.57	0.07	0.47	0.81	-0.27	0.4	0.51	0.54	0.62	0.5	0.54	0.69	0.38	-0.52	0.22	0.39	0.56	0.51
Cash	0.98	0.47	0.98	-0.99	-0.97	0.45		0.86	0.95	0.32	0.98	0.73	-0.36	0.34	0.85	0.98	0.92	0.98	0.99	0.45	0.88	-0.66	0.07	0.93	0.82	0.99
Non Current Assets Total	0.86	0.51	0.83	-0.83	-0.92	0.7	0.86		0.82	0.05	0.84	0.77	-0.36	0.22	0.7	0.9	0.91	0.84	0.88	0.44	0.81	-0.55	0.03	0.83	0.71	0.87
Non Currrent Assets Other	0.92	0.61	0.93	-0.97	-0.94	0.57	0.95	0.82		0.39	0.92	0.8	-0.4	0.55	0.83	0.94	0.85	0.92	0.98	0.58	0.79	-0.63	0.01	0.83	0.79	0.95
Other Assets	0.33	0.3	0.35	-0.36	-0.29	0.07	0.32	0.05	0.39		0.33	0.33	0.03	0.44	0.39	0.31	0.2	0.34	0.33	0.34	0.21	-0.49	0.09	0.21	0.41	0.33
Cash And Short Term Investments	1.0	0.51	1.0	-0.97	-0.96	0.47	0.98	0.84	0.92	0.33		0.76	-0.42	0.31	0.91	0.99	0.93	1.0	0.97	0.49	0.85	-0.75	0.27	0.9	0.87	0.99
Net Receivables	0.79	0.78	0.78	-0.74	-0.84	0.81	0.73	0.77	0.8	0.33	0.76		-0.45	0.61	0.73	0.81	0.8	0.78	0.8	0.71	0.71	-0.77	0.29	0.64	0.87	0.79
Common Stock Shares Outstanding	-0.42	-0.21	-0.43	0.36	0.45	-0.27	-0.36	-0.36	-0.4	0.03	-0.42	-0.45		-0.37	-0.29	-0.44	-0.34	-0.42	-0.44	-0.15	-0.41	0.19	-0.36	-0.35	-0.37	-0.43
Inventory	0.33	0.71	0.35	-0.44	-0.41	0.4	0.34	0.22	0.55	0.44	0.31	0.61	-0.37		0.31	0.36	0.22	0.34	0.43	0.74	0.24	-0.47	-0.08	0.11	0.53	0.37
Other Current Assets	0.9	0.59	0.91	-0.87	-0.81	0.51	0.85	0.7	0.83	0.39	0.91	0.73	-0.29	0.31		0.86	0.81	0.91	0.86	0.56	0.65	-0.74	0.39	0.74	0.79	0.89
Other Stockholder Equity	0.99	0.54	0.99	-0.97	-0.99	0.54	0.98	0.9	0.94	0.31	0.99	0.81	-0.44	0.36	0.86		0.95	0.99	0.99	0.5	0.88	-0.72	0.19	0.9	0.87	1.0
Total Liab	0.94	0.5	0.91	-0.88	-0.94	0.62	0.92	0.91	0.85	0.2	0.93	0.8	-0.34	0.22	0.81	0.95		0.93	0.91	0.45	0.92	-0.72	0.18	0.94	0.85	0.93
Total Current Assets	1.0	0.53	1.0	-0.97	-0.96	0.5	0.98	0.84	0.92	0.34	1.0	0.78	-0.42	0.34	0.91	0.99	0.93		0.97	0.51	0.85	-0.76	0.27	0.89	0.88	0.99
Common Stock	0.98	0.55	0.98	-0.99	-0.98	0.54	0.99	0.88	0.98	0.33	0.97	0.8	-0.44	0.43	0.86	0.99	0.91	0.97		0.52	0.85	-0.67	0.09	0.89	0.83	0.99
Other Current Liab	0.51	0.98	0.51	-0.53	-0.51	0.69	0.45	0.44	0.58	0.34	0.49	0.71	-0.15	0.74	0.56	0.5	0.45	0.51	0.52		0.22	-0.78	0.26	0.18	0.72	0.5
Property Plant And Equipment Net	0.86	0.26	0.83	-0.82	-0.89	0.38	0.88	0.81	0.79	0.21	0.85	0.71	-0.41	0.24	0.65	0.88	0.92	0.85	0.85	0.22		-0.56	0.01	0.95	0.77	0.86
Good Will	-0.76	-0.76	-0.75	0.69	0.7	-0.52	-0.66	-0.55	-0.63	-0.49	-0.75	-0.77	0.19	-0.47	-0.74	-0.72	-0.72	-0.76	-0.67	-0.78	-0.56		-0.5	-0.5	-0.95	-0.71
Short Term Investments	0.26	0.28	0.27	-0.07	-0.11	0.22	0.07	0.03	0.01	0.09	0.27	0.29	-0.36	-0.08	0.39	0.19	0.18	0.27	0.09	0.26	0.01	-0.5		0.02	0.39	0.19
Property Plant And Equipment Gross	0.9	0.23	0.87	-0.87	-0.89	0.39	0.93	0.83	0.83	0.21	0.9	0.64	-0.35	0.11	0.74	0.9	0.94	0.89	0.89	0.18	0.95	-0.5	0.02		0.69	0.9
Intangible Assets	0.88	0.72	0.87	-0.83	-0.86	0.56	0.82	0.71	0.79	0.41	0.87	0.87	-0.37	0.53	0.79	0.87	0.85	0.88	0.83	0.72	0.77	-0.95	0.39	0.69		0.86
Net Tangible Assets	1.0	0.53	0.99	-0.98	-0.98	0.51	0.99	0.87	0.95	0.33	0.99	0.79	-0.43	0.37	0.89	1.0	0.93	0.99	0.99	0.5	0.86	-0.71	0.19	0.9	0.86

Click cells to compare fundamentals

Verona Pharma Account Relationship Matchups

Verona Pharma fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	59.2M	204.2M	186.6M	259.5M	308.1M	323.5M
Total Current Liabilities	12.6M	14.2M	33.4M	19.0M	8.7M	7.7M
Total Stockholder Equity	44.4M	184.9M	148.0M	230.5M	249.3M	261.7M
Net Debt	(28.8M)	(182.0M)	(142.6M)	(217.2M)	(220.4M)	(209.4M)
Retained Earnings	(131.9M)	(207.1M)	(263.7M)	(333.1M)	(388.4M)	(369.0M)
Accounts Payable	1.9M	178K	10.0M	2.9M	3.5M	3.7M
Cash	30.1M	188.0M	148.4M	227.8M	271.8M	285.4M
Non Current Assets Total	5.5M	1.7M	16.5M	16.5M	18.4M	19.3M
Cash And Short Term Investments	40.3M	188.0M	148.4M	227.8M	271.8M	285.4M
Net Receivables	9.8M	8.3M	15.6M	9.3M	11.0M	11.5M
Common Stock Shares Outstanding	13.2M	32.9M	59.1M	66.1M	79.3M	75.3M
Liabilities And Stockholders Equity	59.2M	204.2M	186.6M	259.5M	308.1M	323.5M
Inventory	3.5M	4.5M	4.0M	2.5M	1.0	0.95
Other Current Assets	10.2K	6.3M	6.1M	5.9M	7.0M	7.3M
Other Stockholder Equity	158.0M	364.7M	384.5M	527.6M	599.5M	629.5M
Total Liab	14.8M	19.4M	38.6M	29.0M	58.8M	61.8M
Total Current Assets	53.7M	202.5M	170.1M	243.0M	289.7M	304.2M
Common Stock	6.9M	31.8M	31.9M	40.5M	42.8M	44.9M
Other Current Liab	10.1M	12.4M	22.6M	15.2M	4.0M	5.9M
Property Plant And Equipment Net	1.3M	1.2M	979K	927K	2.9M	3.0M
Good Will	596.0K	559.6K	578.2K	545K	490.5K	466.0K
Short Term Investments	66.0M	57.0M	10.3M	10.3M	11.8M	20.1M
Property Plant And Equipment Gross	43K	1.2M	979K	927K	2.9M	3.0M
Net Tangible Assets	42.2M	184.3M	167.7M	229.9M	264.4M	277.6M
Property Plant Equipment	1.4M	1.2M	979K	927K	1.1M	1.1M
Short Term Debt	603.1K	1.6M	648K	675K	1.2M	694.2K
Non Current Liabilities Total	2.2M	5.1M	5.2M	10.0M	50.1M	52.7M
Capital Lease Obligations	951K	1.3M	934K	880K	3.0M	3.1M
Short Long Term Debt Total	1.2M	5.9M	5.8M	10.6M	51.3M	53.9M
Current Deferred Revenue	0.0	10.9M	22.4M	1.0	1.15	1.09
Net Invested Capital	44.4M	189.5M	152.9M	240.2M	297.7M	174.8M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

When determining whether Verona Pharma PLC offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Verona Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Verona Pharma Plc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Verona Pharma Plc Stock:

How To Invest In Verona

Details

Is Verona Stock a good investment?

Details

What is Verona Pharma's Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Verona Pharma PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Verona Pharma. If investors know Verona will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Verona Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.00)

Revenue Per Share

0.07

Return On Assets

(0.28)

Return On Equity

(0.78)

The market value of Verona Pharma PLC is measured differently than its book value, which is the value of Verona that is recorded on the company's balance sheet. Investors also form their own opinion of Verona Pharma's value that differs from its market value or its book value, called intrinsic value, which is Verona Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Verona Pharma's market value can be influenced by many factors that don't directly affect Verona Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Verona Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Verona Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Verona Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Verona Ebitda vs Selling And Marketing Expenses Analysis

Ebitda vs Selling And Marketing Expenses

Ebitda vs Selling And Marketing Expenses Correlation Analysis

Correlation Coefficient

Ebitda

Selling And Marketing Expenses

Verona Pharma fundamental ratios Correlations

Verona Pharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Verona Pharma fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Net Tangible Assets	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Stockholder Equity
Total Current Assets	+ 1.0	Total Stockholder Equity

Other Stockholder Equity	- 0.99	Retained Earnings
Common Stock	- 0.99	Net Debt
Cash	- 0.99	Net Debt
Net Tangible Assets	- 0.98	Retained Earnings
Common Stock	- 0.98	Retained Earnings
Net Tangible Assets	- 0.98	Net Debt